A patient aged 40-75 with diabetes presents for follow-up. What should the statin recommendations be?

A patient aged 40-75 with diabetes presents for follow-up. What should the statin recommendations be?

• A. Moderate-intensity statin therapy without calculating 10-year risk
• B. High-intensity statin therapy for all
• C. No statin unless ASCVD present
• D. Ezetimibe added to statin

Answer: (A)

In adults aged 40–75 with diabetes, starting statin therapy for primary prevention is recommended regardless of calculated 10-year ASCVD risk. Diabetes itself places patients at higher risk, so a moderate-intensity statin is indicated to lower LDL by roughly 30–49% and reduce ASCVD events without the greater side effects profile that comes with higher-dose therapy. This approach is preferred over waiting for an elevated 10-year risk score or treating only after ASCVD develops. Choosing a moderate-intensity statin (for example, a statin that typically lowers LDL by about a third) strikes a balance between beneficio and tolerability. High-intensity statin therapy for everyone isn’t necessary unless there are additional high-risk features or very high baseline risk. Not treating with statins in a diabetic patient without ASCVD misses a proven preventive measure. Adding ezetimibe is usually reserved for cases where LDL targets aren’t reached with maximally tolerated statin, or if statin therapy isn’t tolerated, rather than as initial therapy.

In adults aged 40–75 with diabetes, starting statin therapy for primary prevention is recommended regardless of calculated 10-year ASCVD risk. Diabetes itself places patients at higher risk, so a moderate-intensity statin is indicated to lower LDL by roughly 30–49% and reduce ASCVD events without the greater side effects profile that comes with higher-dose therapy. This approach is preferred over waiting for an elevated 10-year risk score or treating only after ASCVD develops.

Choosing a moderate-intensity statin (for example, a statin that typically lowers LDL by about a third) strikes a balance between beneficio and tolerability. High-intensity statin therapy for everyone isn’t necessary unless there are additional high-risk features or very high baseline risk. Not treating with statins in a diabetic patient without ASCVD misses a proven preventive measure. Adding ezetimibe is usually reserved for cases where LDL targets aren’t reached with maximally tolerated statin, or if statin therapy isn’t tolerated, rather than as initial therapy.